Atara Biotherapeutics, Inc.
ATRA
$9.91
-$0.32-3.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.19M | 23.14M | 120.77M | 151.93M | 188.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.19M | 23.14M | 120.77M | 151.93M | 188.67M |
| Cost of Revenue | 5.63M | 11.02M | 50.25M | 71.52M | 120.02M |
| Gross Profit | 562.00K | 12.12M | 70.52M | 80.41M | 68.65M |
| SG&A Expenses | 14.09M | 16.98M | 23.39M | 29.36M | 35.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.58M | 30.85M | 76.50M | 114.35M | 169.29M |
| Operating Income | -16.39M | -7.71M | 44.27M | 37.59M | 19.38M |
| Income Before Tax | -16.66M | -9.44M | 32.72M | 23.41M | 5.76M |
| Income Tax Expenses | 29.00K | 31.00K | 31.00K | 12.00K | -33.00K |
| Earnings from Continuing Operations | -16.69 | -9.47 | 32.69 | 23.40 | 5.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.69M | -9.47M | 32.69M | 23.40M | 5.80M |
| EBIT | -16.39M | -7.71M | 44.27M | 37.59M | 19.38M |
| EBITDA | -14.94M | -6.04M | 47.71M | 41.07M | 24.22M |
| EPS Basic | -1.18 | -0.67 | 3.16 | 2.22 | -0.39 |
| Normalized Basic EPS | -0.84 | -0.47 | 2.49 | 2.04 | 0.40 |
| EPS Diluted | -1.19 | -0.67 | 3.12 | 2.18 | -0.43 |
| Normalized Diluted EPS | -0.84 | -0.47 | 2.47 | 2.02 | 0.38 |
| Average Basic Shares Outstanding | 56.30M | 53.46M | 50.15M | 47.24M | 41.14M |
| Average Diluted Shares Outstanding | 56.30M | 53.58M | 50.35M | 47.44M | 41.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |